In plain terms: BPC-157 (Body Protection Compound 157) has not yet been tested in a human trial designed to measure the outcome relevant here. The available human research does not yet answer the question.
BPC-157 (Body Protection Compound 157)
The evidence as the record states it
Vasireddi et al. (HSS Journal, 2025; PMID 40756949) - systematic review: 544 articles screened, 36 included, of which 35 were preclinical and 1 was clinical; the review reports that no clinical safety data were found. McGuire et al. (Current Reviews in Musculoskeletal Medicine, 2025; PMID 40789979) - narrative review: three pilot studies have examined BPC-157 in humans, and the review characterizes the compound as investigational. Mendias and Awan (Sports Medicine, 2026; PMID 41966639) - narrative review of approved and unapproved peptides: favorable tissue-repair outcomes in animal models, rigorous human safety data scarce. The entire human record consists of three uncontrolled reports sharing one lead author, one from a named Orlando clinic and two from an unnamed private clinic. Lee et al. (Alternative Therapies in Health and Medicine, 2021; PMID 34324435) - retrospective one-year chart review of intra-articular injection for knee pain in which improvement was captured by telephone self-report and no measurement instrument was used. Lee et al. (Alternative Therapies in Health and Medicine, 2024; PMID 39325560) - single-arm pilot in 12 women with interstitial cystitis, no control group. Lee et al. (Alternative Therapies in Health and Medicine, 2025; PMID 40131143) - intravenous safety pilot in 2 subjects, both of whom had received intravenous BPC-157 before the study. Cox et al. (Drug Testing and Analysis, 2017; PMID 28035768) - detection method developed for confiscated BPC-157 vials; the compound is prohibited in sport. Sikiric et al. (Curr Med Chem, 2012; PMID 22300085), from the group that developed the peptide, state that BPC 157 (PL 14736) was tested in a phase II clinical trial for inflammatory bowel disease; no result of that trial is indexed. Grade D Route 1: no result of a human randomized controlled trial of BPC-157 has been published.
Why Grade D Route 1 and not Grade C
Grade D Route 1 applies when no qualifying human randomized trial has tested this compound or intervention against the relevant endpoint. Absence confirmed: (BPC-157[tiab] OR "BPC 157"[tiab]) AND (randomized controlled trial[pt] OR clinical trial[pt]) (PubMed, October 2026)
The first qualifying human RCT with a meaningful endpoint would move this to Grade C or higher, depending on what it shows.
What would move this grade
The first qualifying randomized controlled trial in humans, testing this intervention against a meaningful aging-relevant endpoint, would initiate grading. Depending on the result, it could land at any grade from A to D.